News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,547 Results
Type
Article (42716)
Company Profile (436)
Press Release (673395)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208908)
Career Advice (2064)
Deals (36042)
Drug Delivery (104)
Drug Development (83624)
Employer Resources (174)
FDA (16451)
Job Trends (15125)
News (353121)
Policy (33139)
Tag
Academia (2650)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (51006)
ALS (99)
Alzheimer's disease (1436)
Antibody-drug conjugate (ADC) (147)
Approvals (16430)
Artificial intelligence (279)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11854)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (299)
Cancer (2375)
Cardiovascular disease (191)
Career advice (1724)
Career pathing (30)
CAR-T (161)
Cell therapy (456)
Cervical cancer (20)
Clinical research (67889)
Collaboration (899)
Company closure (2)
Compensation (566)
Complete response letters (25)
COVID-19 (2658)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2335)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6442)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (127)
Drug pricing (112)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88244)
Editorial (43)
Employer branding (21)
Employer resources (148)
Events (116256)
Executive appointments (758)
FDA (17834)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (21)
Gene therapy (338)
GLP-1 (756)
Government (4530)
Grass and pollen (4)
Guidances (150)
Healthcare (19189)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (136)
Indications (30)
Infectious disease (2805)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (322)
IPO (16808)
IRA (44)
Job creations (3710)
Job search strategy (1464)
Kidney cancer (10)
Labor market (43)
Layoffs (506)
Leadership (18)
Legal (8000)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (333)
MASH (76)
Medical device (13540)
Medtech (13545)
Mergers & acquisitions (19798)
Metabolic disorders (738)
Multiple sclerosis (84)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2023)
NextGen: Class of 2025 (6779)
Non-profit (4565)
Now hiring (40)
Obesity (394)
Opinion (225)
Ovarian cancer (82)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (116)
Peanut (47)
People (58789)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21334)
Phase II (29963)
Phase III (22142)
Pipeline (1370)
Policy (156)
Postmarket research (2605)
Preclinical (9159)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (409)
Real estate (6021)
Recruiting (66)
Regulatory (22814)
Reports (47)
Research institute (2423)
Resumes & cover letters (355)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (79)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3767)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (49)
The Weekly (49)
Vaccines (717)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Last 7 days (951)
Last 30 days (3063)
Last 365 days (33360)
2025 (11996)
2024 (36308)
2023 (41036)
2022 (52290)
2021 (56775)
2020 (54970)
2019 (47478)
2018 (35755)
2017 (33055)
2016 (32399)
2015 (38439)
2014 (32219)
2013 (27146)
2012 (29263)
2011 (29914)
2010 (28046)
Location
Africa (747)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39351)
Australia (6555)
California (6512)
Canada (2073)
China (548)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (86101)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (565)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (939)
Massachusetts (4923)
Michigan (225)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1821)
New Mexico (30)
New York (1821)
North Carolina (1054)
North Dakota (8)
Northern California (2838)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1435)
Puerto Rico (13)
Rhode Island (34)
South America (1116)
South Carolina (25)
South Dakota (1)
Southern California (2440)
Tennessee (105)
Texas (964)
United States (24489)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
716,547 Results for "black diamond therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
The French pharma is getting Black Diamond’s de-prioritized molecule for non-small cell lung cancers with specific mutations whose development had been paused to save money.
March 19, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Black Diamond Therapeutics to Participate in Upcoming April 2025 Investor Conferences
April 1, 2025
·
1 min read
Press Releases
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025
·
6 min read
Press Releases
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 7, 2025
·
7 min read
Genetown
Black Diamond Therapeutics to Participate in Jefferies 2024 Global Healthcare Conference
Black Diamond Therapeutics, Inc. announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.
May 29, 2024
·
1 min read
Business
Black Diamond Therapeutics Announces Changes to Board of Directors - April 11, 2024
Black Diamond Therapeutics, Inc. today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company’s Board of Directors.
April 11, 2024
·
5 min read
Genetown
Black Diamond Therapeutics to Participate in Upcoming April 2024 Investor Conferences
Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced its participation in upcoming investor conferences.
April 3, 2024
·
1 min read
Press Releases
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 4, 2024
·
1 min read
Business
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Genetown
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.
April 24, 2024
·
3 min read
1 of 71,655
Next
